Program
mirvetuximab soravtansine
Also written as “Mirvetuximab Soravtansine”, “Mirvetuximab soravtansine” and “TAK-853”.
Its studies are mostly in Carcinoma, Ovarian Epithelial · Ovarian Neoplasms · Fallopian Tube Neoplasms · Neoplasms, led by 5 companies.
Drug pageMirvetuximab soravtansine: every studyMany companies study it; this page follows only the 15 they lead. All 28 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVieits history only | 115 open or running | phase 3since Dec 10, 2015 | May 30, 2012 | Nov 2026phase 2 · NCT05456685 |
| AGO Research | 11 open or running | phase 2since Feb 10, 2020 | Feb 10, 2020 | none ahead |
| Huadong Medicineits history only | 10 open or running | phase 3since Nov 14, 2022 | Nov 14, 2022 | none ahead |
| Pheast Therapeuticsits history only | 11 open or running | phase 1since Feb 10, 2025 | Feb 10, 2025 | Apr 2029phase 1 · NCT06840886 |
| Takedaits history only | 11 open or running | phase 2since Apr 26, 2024 | Apr 26, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AGO Research only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2015Named mirvetuximab soravtansineINNProposed as its International Nonproprietary Name in WHO's List 113 · before, TAK-853
- Feb 10, 2020First study: phase 2 study in Recurrent Epithelial Ovarian, Fallopian or Peritoneal CarcinomaFirst studyNCT04274426 · 136 enrolled · Germany
TargetBeta
“An immunoconjugate consisting of the humanized monoclonal antibody M9346A against folate receptor 1 (FOLR1) ”NCIt, by rule
“Folate receptor alpha binding agent”ChEMBL 37, by rule
Other programs on FOLR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| rinatabart sesutecanrule | Genmab | phase 3 | 9 |
| torvutatug samrotecan | AstraZeneca | phase 3 | 5 |
| sofetabart mipitecan | Eli Lilly | phase 3 | 2 |
| opugotamig olatansine | AbbVie | phase 2 | 2 |
| Anti-Folate Receptor Alpha Antibody-drug Conjugate ABBV-901 | AbbVie | phase 1 | 1 |
| Anti-FRa/Anti-CD3 Bispecific TCE NTB-928rule | teneoseven-inc | phase 1 | 1 |
Studies
The one study AGO Research leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04274426Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma · Germany | 2 | Active, not recruiting | Dec 3, 2025 | 136 |
How it is read
Names in the registry
- “Mirvetuximab Soravtansine”, 8 entries
- “Mirvetuximab soravtansine”, 5 entries
- “TAK-853”, 1 entry
- “Mirvetuximab soravtansine plus Bevacizumab”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Ovarian Epithelial, 6 studies
- Ovarian Neoplasms, 4 studies
- Fallopian Tube Neoplasms, 2 studies
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.